Dr. Ricardo Diez Valle

Dr. Ricardo Díez Valle is a highly skilled neurosurgeon specializing in the treatment of brain tumors, particularly gliomas, meningiomas, and neurinomas. He serves as the Head of the Neurosurgery Department at Ruber Internacional Hospital in Madrid, where he leads a specialized team in advanced neurosurgical techniques. With extensive training in microneurosurgery and neuro-oncology, he focuses on minimally invasive and precision-based approaches to optimize patient outcomes.

Dr. Díez Valle is an active member of prestigious medical societies, including the Spanish Society of Neurosurgery (SENEC), and contributes to cutting-edge research in brain tumor treatment. His expertise encompasses both surgical and multidisciplinary management of complex neurological conditions, ensuring personalized care for each patient. Recognized for his surgical skill and dedication to innovation, he has participated in numerous clinical studies and collaborates with leading oncologists and radiotherapists to develop integrated treatment protocols.

Committed to medical education, he mentors young neurosurgeons and frequently shares his knowledge at national and international conferences. His patient-centered approach, combined with his technical excellence, has established him as a leading figure in neurosurgery, particularly in the field of brain tumor surgery.

Head of the Neurosurgery Department
Ruber International Hospital , Quironsalud, Spain (since 2019)

Neurosurgeon
University Clinic of Navarra, Spain (2007 – 2019)

Head of the Neurosurgery Department
MD Anderson International Hospital, Spain (2003 – 2007)

Neurosurgeon 
Ramón y Cajal Hospital (1996 – 2007)


Degree:

Doctorate "cum laude" in Applied Medical Research
University of Navarra, Spain. (2011)

Neurosurgery Specialist
Ramón y Cajal Hospital and Ministry of Education, Spain, (1996)

Bachelor of Medicine and Surgery 
Complutense University and Ministry of Education, Spain. (1988)

Teaching:

 Neurosurgery Resident Teaching (1996 – present)

Associate Professor, University of Navarra. (2007 – 2019)

Research:

- "Phase I trial of DNX-2440 oncolytic adenovirus in patients with recurrent glioblastoma." D2440GBM1

-NEO-NIVO "Phase II study with neoadjuvant nivolumab in patients with glioblastoma multiforme."

-Phase I Trial of DNX-2401 for Diffuse Intrinsic Pontine Glioma Newly Diagnosed in Pediatric Patients.

-"Prospective phase II study of the efficacy and safety of autologous dendritic cell vaccination in patients with glioblastoma multiforme after complete surgical resection using fluorescence microscopy."

-"Phase I study of the combination of the oncolytic virus DNX-2401 with a short course of temozolomide in the treatment of patients with first relapse of glioblastoma." D24GBM Eudra CT 2011-005935-21

-Sociedad Española de Neurocirugía (SENEC).

-American Association of Neurological Surgeons (AANS).

-Congress of Neurological Surgeons (CNS).

2023| Long-Term Outcomes in Resected IDH-Mutant Subtypes of Diffuse Low-Grade Glioma. J Clin Oncol. 2023 Apr 10;41(11):1979-1981. doi: 10.1200/JCO.22.02428. Epub 2023 Feb 28. PMID: 36854064

2022| Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma. N Engl J Med. 2022 Jun 30;386(26):2471-2481. doi: 10.1056/NEJMoa2202028. PMID: 35767439.

2021| Ki-67 Proliferative Activity in the Tumor Margins as a Robust Prognosis Factor in Glioblastoma Patients. J Neurol Surg A Cent Eur Neurosurg. 2021 Jan;82(1):53-58. doi: 10.1055/s-0040-1709730. Epub 2020 Dec 1.PMID: 33260244

2019| Intraoperative fluorescence diagnosis in the brain: a systematic review and suggestions for future standards on reporting diagnostic accuracy and clinical utility. Acta Neurochir (Wien). 2019 Jul 30. PMID: 31363920 PMCID: PMC6739423 DOI: 10.1007/s00701-019-04007-y

2019| Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. Nat Med. 2019 Feb 11. PMID: 30742120 DOI: 10.1038/s41591-018-0339-5